ImmunityBio to Participate in the Jefferies London Healthcare Conference

IBRX 10.21.2024

Full Press ReleaseSEC FilingsOur IBRX Tweets

About Gravity Analytica

Recent News

  • 02.13.2025 - February 13, 2025 - February 15, 2025 : ASCO GU
  • 01.23.2025 - January 23, 2025 - January 25, 2025 : ASCO GI
  • 01.15.2025 - ImmunityBio Provides Regulatory Update on Anticipated FDA Submissions in 2025 Following Meeting with the Agency

Recent Filings

  • 01.03.2025 - 4 Statement of changes in beneficial ownership of securities
PDF Version

CULVER CITY, Calif.--(BUSINESS WIRE)--Oct. 21, 2024-- Immunotherapy innovatorImmunityBio, Inc.(NASDAQ: IBRX), announced today that company executives will be participating in theJefferies London Healthcare Conference, which is taking placeNovember 19-21at the Waldorf Hilton London.

Details of the presentation can be found below.

Jefferies London Healthcare Conference

Date:

Tuesday, November 19, 2024

Time:

3:00 PMGT

Format:

Fireside chat withImmunityBiocompany executives

A replay of the recorded fireside presentation will be available through the Events and Presentations section of theImmunityBiowebsite athttps://ir.immunitybio.com/for 90 days.

AboutImmunityBio

ImmunityBiois a vertically-integrated biotechnology company developing next-generation therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. The company’s range of immunotherapy and cell therapy platforms, alone and together, act to drive and sustain an immune response with the goal of creating durable and safe protection against disease. Designated an FDA Breakthrough Therapy, ANKTIVA®is the first FDA-approved immunotherapy for non-muscle invasive bladder cancer CIS that activates natural killer cells, T cells, and memory T cells for a long-duration response. The company is applying its science and platforms to treating cancers, including the development of potential cancer vaccines, as well as developing immunotherapies and cell therapies that we believe sharply reduce or eliminate the need for standard high-dose chemotherapy. These platforms and their associated product candidates are designed to be more effective, accessible, and easily administered than current standards of care in oncology and infectious diseases.

For more information, visitwww.immunitybio.comand connect with us onX(Twitter),Facebook,LinkedIn, andInstagram.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements regarding conference participation and timing, the development of therapeutics for cancer and infectious diseases, potential benefits to patients, potential treatment outcomes for patients, the described mechanism of action and results and contributions therefrom, potential future uses and applications of ANKTIVA and use in cancer vaccines and across multiple tumor types, and ImmunityBio’s approved product and investigational agents as compared to existing treatment options, among others. Statements in this presentation that are not statements of historical fact are considered forward-looking statements, which are usually identified by the use of words such as “anticipates,” “believes,” “continues,” “goal,” “could,” “estimates,” “scheduled,” “expects,” “intends,” “may,” “plans,” “potential,” “predicts,” “indicate,” “projects,” “is,” “seeks,” “should,” “will,” “strategy,” and variations of such words or similar expressions. Statements of past performance, efforts, or results of our preclinical and clinical trials, about which inferences or assumptions may be made, can also be forward-looking statements and are not indicative of future performance or results. Forward-looking statements are neither forecasts, promises nor guarantees, and are based on the current beliefs of ImmunityBio’s management as well as assumptions made by and information currently available toImmunityBio. Such information may be limited or incomplete, and ImmunityBio’s statements should not be read to indicate that it has conducted a thorough inquiry into, or review of, all potentially available relevant information. Such statements reflect the current views ofImmunityBiowith respect to future events and are subject to known and unknown risks, including business, regulatory, economic and competitive risks, uncertainties, contingencies and assumptions aboutImmunityBio, including, without limitation, (i) risks and uncertainties related to the regulatory submission and review process, (ii) the ability ofImmunityBioto fund its ongoing and anticipated clinical trials, (iii) whether clinical trials will result in registrational pathways and the risks and uncertainties regarding the regulatory submission, review and approval process, (iv) the ability ofImmunityBioto continue its planned preclinical and clinical development of its development programs through itself and/or its investigators, and the timing and success of any such continued preclinical and clinical development, patient enrollment and planned regulatory submissions, (v) potential delays in product availability and regulatory approvals, (vi) ImmunityBio’s ability to retain and hire key personnel, (vii) ImmunityBio’s ability to obtain additional financing to fund its operations and complete the development and commercialization of its various product candidates, (viii) potential product shortages or manufacturing disruptions that may impact the availability and timing of product, (ix) ImmunityBio’s ability to successfully commercialize its approved product and product candidates, (x) ImmunityBio’s ability to scale its manufacturing and commercial supply operations for its approved product and future approved products, and (xi) ImmunityBio’s ability to obtain, maintain, protect and enforce patent protection and other proprietary rights for its product candidates and technologies. More details about these and other risks that may impact ImmunityBio’s business are described under the heading “Risk Factors” in the Company’s Form 10-K filed with theU.S. Securities and Exchange Commission(“SEC”) onMarch 19, 2024and the Company’s Form 10-Q filed with theSEConAugust 12, 2024, and in subsequent filings made byImmunityBiowith theSEC, which are available on the SEC’s website atwww.sec.gov.ImmunityBiocautions you not to place undue reliance on any forward looking statements, which speak only as of the date hereof.ImmunityBiodoes not undertake any duty to update any forward-looking statement or other information in this press release, except to the extent required by law.

View source version onbusinesswire.com:https://www.businesswire.com/news/home/20241021229120/en/

InvestorsHemanth Ramaprakash, PhD, MBAImmunityBio, Inc.+1 858-746-9289Hemanth.Ramaprakash@ImmunityBio.com

MediaSarah SingletonImmunityBio, Inc.+1 415-290-8045Sarah.Singleton@ImmunityBio.com

Source:ImmunityBio, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com